SymTrak-8 as a Brief Measure for Assessing Symptoms in Older Adults.
SymTrak-8 as a Brief Measure for Assessing Symptoms in Older Adults.
复制标题
SymTrak-8 作为评估老年人症状的简单措施。
DOI：
10.1007/s11606-020-06329-5
复制
发表时间：
2021
影响因子：
5.7
通讯作者：
Stump,TimothyE
中科院分区：
文献类型：
--
作者：
Monahan,PatrickO;Kroenke,Kurt;Stump,TimothyE
背景患者和患者报告的23项SymTrak量表经验证可用于监测老年人多种慢性疾病（MCC）相关的临床可操作症状和损伤。项目捕捉身体和情绪症状以及身体和认知功能的损伤。当回答负担是一个问题时，最好使用一个简短的SymTrak。开发和验证8项SymTrak。设计和验证SymTrak验证研究的二次分析; 600名参与者（200名患者-护理人员二人组; 200名没有指定护理人员的患者）。主要测量人口统计学问题，SymTrak，和健康效用指数马克3（HUI 3）。关键结果SymTrak-8表现出良好的拟合，一个单因素模型，使用验证性因素分析（CFA）。基线SymTrak-8总分与基线SymTrak-8总分之间的高标准化线性回归系数（STB）支持并行标准有效性。（自变量）和基线基于HUI 3偏好的总体HRQOL效用评分（因变量; 0 =死亡，1 =完全健康），在调整人口统计学、共病状况和药物后，强度与SymTrak-23相当（患者报告时，SymTrak-8和SymTrak-23的STB分别为-0.81和-0.84;患者报告时，STB分别为-0.60和-0.62）。SymTrak-8的α系数（0.74; 0.76）和24小时重测信度（0.83; 0.87）分别较高。简短的和父母的SymTrak量表之间的收敛相关性很高（0.94）。SymTrak-8与SymTrak-23和HUI 3表现出近似正态性和线性关系。重要的是，SymTrak-8的3个月变化对检测标准（3个月可靠变化类别;改善，稳定，下降，HUI 3总体效用）敏感，结果与SymTrak-23.ConclusionsSymTrak-8总评分显示内部可靠性，重测信度，标准效度和敏感性变化与SymTrak-23相当。因此，当反应负担是一个问题时，患者或患者报告的SymTrak-8是识别和监测多发性骨髓瘤患者症状和功能障碍的综合效应的可行选择。
BackgroundPatient- and caregiver-reported 23-item SymTrak scales were validated for monitoring clinically actionable symptoms and impairments associated with multiple chronic conditions (MCCs) in older adults. Items capture physical and emotional symptoms and impairments in physical and cognitive functioning. An abbreviated SymTrak is desirable when response burden is a concern.ObjectiveDevelop and validate the 8-item SymTrak.Design and ParticipantsSecondary analysis of SymTrak validation study; 600 participants (200 patient-caregiver dyads; 200 patients without an identified caregiver).Main MeasuresDemographic questions, SymTrak, and Health Utility Index Mark 3 (HUI3).Key ResultsSymTrak-8 demonstrated good fit to a one-factor model using confirmatory factor analysis (CFA). Concurrent criterion validity was supported by high standardized linear regression coefficients (STB) between baseline SymTrak-8 total score (independent variable) and baseline HUI3 preference-based overall HRQOL utility score (dependent variable; 0 = death, 1 = perfect health), after adjusting for demographics, comorbid conditions, and medications, with strength comparable to SymTrak-23 (STB = − 0.81 and − 0.84, respectively, for SymTrak-8 and SymTrak-23, when patient-reported; and − 0.60 and − 0.62, respectively, when caregiver-reported). Coefficient alpha (0.74; 0.76) and 24-h test–retest reliability (0.83; 0.87) were high for SymTrak-8 for patients and caregivers, respectively. The convergent correlation between brief and parent SymTrak scales was high (0.94). SymTrak-8 demonstrated approximate normality and a linear relationship with SymTrak-23 and HUI3. Importantly, a 3-month change in SymTrak-8 was sensitive to detecting the criterion (3-month reliable change categories; improved, stable, declined in HUI3 overall utility), with results comparable to SymTrak-23.ConclusionsSymTrak-8 total score demonstrates internal reliably, test–retest reliability, criterion validity, and sensitivity to change that are comparable to SymTrak-23. Thus, patient- or caregiver-reported SymTrak-8 is a viable option for identifying and monitoring the aggregate effect of symptoms and functional impairments in patients with multimorbidity when response burden is a concern.